Interferon Therapy of Chronic Hepatitis B

Chronic hepatitis B remains a major global health challenge because persistent hepatitis B virus infection can lead to cirrhosis, liver failure, and hepatocellular carcinoma. Interferon-based therapy, particularly pegylated interferon alfa, is an immune-modulating treatment option that is administered for a defined course rather than indefinitely. Its use depends on viral replication, alanine aminotransferase levels, liver disease stage, hepatitis B e antigen status, prior treatment, and patient suitability. Current clinical practice generally balances the possibility of sustained immune control against tolerability, contraindications, and the availability of long-term oral nucleos(t)ide analogues.

Management is increasingly shaped by individualized assessment rather than a single treatment pathway. Clinicians evaluate fibrosis, cirrhosis status, viral load, hepatitis B e antigen status, comorbidities, pregnancy considerations, psychiatric history, and treatment goals before selecting interferon or an oral antiviral. Pegylated interferon remains relevant where a finite treatment course and the possibility of durable virologic or serologic response are valued, while long-term oral therapy is often preferred when rapid viral suppression, broad eligibility, or improved tolerability is the priority. Greater use of noninvasive fibrosis assessment, standardized monitoring, and hepatitis B reactivation prevention is also influencing treatment decisions.

Artificial intelligence is being evaluated for hepatitis B screening, interpretation of laboratory and imaging data, fibrosis assessment, hepatocellular carcinoma surveillance, and prediction of treatment response. These applications may help identify patients requiring specialist review and improve consistency in longitudinal monitoring. However, clinical deployment remains constrained by data quality, population bias, explainability, privacy, and the need for prospective validation. AI should therefore augment, rather than replace, guideline-based assessment and clinician judgment, particularly when deciding whether interferon is appropriate for patients with complex liver disease or substantial contraindication risk.

North America generally combines specialist hepatology capacity with strong laboratory infrastructure, although diagnosis and linkage to care remain uneven. Europe emphasizes guideline-based treatment, fibrosis evaluation, and coordinated viral-hepatitis elimination programs. Asia-Pacific contains a substantial share of the global hepatitis B burden and includes both advanced treatment systems and settings where screening, affordability, and specialist access remain barriers. The Middle East is characterized by varied national screening policies, migration-related care needs, and differences in specialist availability. Africa continues to face major gaps in diagnosis, surveillance, and access to antiviral care, making task-sharing and decentralized services important. Latin America has expanded public-health attention to viral hepatitis, but fragmented diagnosis, reimbursement differences, and unequal access to specialist monitoring continue to affect interferon use.

ASEAN countries face diverse hepatitis B epidemiology, health-system capacity, and reimbursement environments, so treatment pathways vary considerably across the group. BRICS members combine large affected populations with wide differences in screening coverage, laboratory access, and public-sector treatment delivery. The European Union benefits from shared clinical guidance and cross-border public-health priorities, while national reimbursement and service organization remain distinct. G7 systems generally have strong diagnostic and specialist capacity but still confront underdiagnosis, migrant-health needs, and inequitable access. GCC countries often have comparatively well-resourced tertiary services, alongside the need for coordinated screening and continuity of care among mobile populations. NATO members span highly varied health systems, making alliance-wide clinical alignment less uniform than national or regional policy frameworks.

Australia supports structured hepatitis B care through specialist and primary-care pathways, while regional access remains important. Brazil and Mexico continue to address diagnosis and linkage-to-care gaps through public-health systems with uneven local capacity. Canada and the United States have advanced specialist services but persistent disparities in screening and care among underserved and migrant communities. China and India carry substantial hepatitis B burdens and require broad screening, affordable diagnostics, and scalable specialist support. Japan and South Korea have established hepatology expertise and surveillance practices, with treatment decisions guided by disease stage and patient characteristics. France, Germany, Italy, Spain, and the United Kingdom operate within mature clinical systems, but national reimbursement, referral pathways, and elimination priorities differ. Russia’s care environment reflects substantial regional variation in diagnostic access and specialist availability.

Leaders should align interferon pathways with current hepatitis B guidelines and use structured eligibility checks covering liver disease severity, psychiatric history, autoimmune conditions, cytopenias, thyroid disease, pregnancy, and treatment interactions. Strengthening reflex testing, noninvasive fibrosis assessment, and documented linkage to hepatology can reduce avoidable delays. Care teams should provide clear counseling on adverse effects, adherence, contraception where relevant, and laboratory monitoring, while maintaining surveillance for hepatocellular carcinoma in patients who remain at risk. Organizations can improve access by supporting decentralized testing, nurse-led follow-up, culturally appropriate education, and referral networks. Digital tools and AI should be introduced only with clinical validation, governance, human oversight, and transparent performance monitoring.

This executive summary uses a structured synthesis of authoritative hepatitis B guidance, peer-reviewed clinical evidence, public-health information, and established treatment principles. The assessment considers interferon’s mechanism, patient-selection criteria, safety and monitoring requirements, competing oral antiviral pathways, diagnostic infrastructure, reimbursement context, and regional implementation conditions. Geographic insights are organized around the requested regions, economic and policy groups, and countries, while avoiding unsupported quantitative claims. Because treatment recommendations and access conditions evolve, decisions should be checked against current national guidelines, regulatory information, and local clinical protocols.

Interferon therapy retains a role for carefully selected people with chronic hepatitis B, particularly when a defined treatment duration and the possibility of durable immune control are clinically meaningful. Its use is limited by adverse-effect burden, contraindications, monitoring demands, and the suitability of alternative oral antivirals for many patients. The strongest pathway forward combines earlier diagnosis, reliable fibrosis and viral assessment, individualized treatment selection, equitable specialist support, and long-term liver-cancer surveillance. Regional and national implementation will depend on integrating clinical quality with affordable testing, consistent referral systems, and patient-centered follow-up.